We speculate that WNT ligand inhibition might be a therapeutic option for this type of CRC as reported for CRC with RNF43 mutations or R-spondin fusions (Storm et al., 2016, Yan et al., 2017, Han et al., 2017). The gene discussed is RNF43; the disease is colorectal carcinoma.